AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01033942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Many Men, Many Voices (3MV)
Description: Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
Study NCT01033942 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Many Men, Many Voices (3MV)
Description: Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
Study NCT04415918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezlotoxumab Injection
Description: A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments.
Study NCT03892733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: calorie health education knowledge and skills
Description: 45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
Study NCT02328105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dosing: AUC = 6; on Day 1
Study NCT02328105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m\^2; Days 1, 8, 15
Study NCT02932943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for weekly IV injections.
Study NCT02932943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study NCT02748031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slit-lamp-adapted anterior segmental photography
Description: The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
Study NCT02257671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptive
Description: Neovletta
Study NCT02257671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral contraceptive
Description: Neovletta
Study NCT03557996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: SDF will be applied with a brush
Study NCT03557996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Varnish
Description: NaF will be applied with a brush
Study NCT00555308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emergency department targeted ultrasound imaging
Description: bedside ultrasound performed by emergency physician to identify hydronephrosis
Study NCT01086839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride 6%
Description: * one ampoule sodium chloride 6% per day~* inhalation use~* for 28 days
Study NCT01086839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0,9%
Description: * one ampoule sodium chloride 0,9% per day~* inhalation use~* for 28 days
Study NCT02715297 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT to the resection cavity
Description: 46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
Study NCT02463552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
Study NCT03161054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).
Study NCT03161054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Study NCT02463552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
Study NCT03357939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX03
Description: A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
Study NCT03357939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
Study NCT03989739 — intervention group
Intervention type: DEVICE
Intervention: Da Vinci
Study NCT03161054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
Study NCT02591329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mail-out hard copy materials (education plus self-regulatory strategies examples)
Study NCT02591329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study NCT02582177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candicort®
Description: Apply on the affected area and around it twice a day
Study NCT02582177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizoral®
Description: Apply on the affected area and around it twice a day
Study NCT03161054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner).
Study NCT02582177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baycuten N®
Description: Apply on the affected area and around it twice a day
Study NCT03161054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
Study NCT02204462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FBnTP
Description: A PET imaging radiotracer
Study NCT03819127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG Oral Tablet
Study NCT03819127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Pill
Study NCT03819127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Pill
Study NCT01060488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GHRH+Arg, GHRH+Arg, ITT
Description: GHRH+Arg repeatability test (2 tests) + comparison with one IT test
Study NCT01060488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ITT, ITT, GHRH+Arg.
Description: IT repeatability test (2 tests) + comparison with one GHRH+Arg test
Study NCT00869596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
Study NCT00869596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to fluticasone
Description: Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
Study NCT00869596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Lipopolysaccharide (LPS)
Description: 20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
Study NCT00869596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Lipopolysaccharide (LPS)
Description: 20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
Study NCT00869596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: albuterol
Description: Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
Study NCT00869596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: albuterol
Description: Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
Study NCT01725399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Juice
Study NCT01725399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Study NCT00512668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given intramuscularly
Study NCT00512668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously
Study NCT00512668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given PO
Study NCT00512668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilutamide
Description: Given PO
Study NCT00512668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Given PO
Study NCT00512668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study NCT00512668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT05743855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Nutritional Supplement + Chiropract sessions
Study NCT05743855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Chiropractic sessions
Study NCT02097277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986036
Study NCT02097277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Matching with BMS-986036)
Study NCT02097277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Matching with BMS-986036)
Study NCT01381510 — intervention group
Intervention type: DRUG
Intervention: 5-alpha Reductase Inhibitor (5ARI)
Description: A 5ARI: Either dutasteride or finisteride
Study NCT02841735 — intervention group
Intervention type: DEVICE
Intervention: Smartphone breathalyzer device/app use
Description: Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
Study NCT02841735 — intervention group
Intervention type: DEVICE
Intervention: BAC estimator app use
Description: Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
Study NCT02841735 — intervention group
Intervention type: DEVICE
Intervention: Text messaging procedure
Description: Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
Study NCT03006120 — intervention group
Intervention type: PROCEDURE
Intervention: Retroperitoneal hematoma due to cardiac catheterization
Study NCT01533220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naphazoline hydrocloride
Description: 02 drops into each nostril, 04 times a day for 03 days
Study NCT01533220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naphazoline hydrocloride + Pheniramine Maleate + Panthenol
Description: 02 drops into each nostril each 12 hours for 03 days
Study NCT03320369 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Elemental Diet Therapy
Description: Elemental diet is a formula composed of amino-acids, carbohydrates, and lipids that is 100% nutritionally complete
Study NCT01055912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
Study NCT01055912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
Study NCT04488185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg administered s.c. (2 single-use prefilled syringes of 150 mg/mL), on Days 1, 8, 15, 22, 29, 57, 85.
Study NCT04488185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered s.c. (2 single-use prefilled 1 mL syringes) on Days 1, 8, 15, 22, 29, 57, 85.
Study NCT02174172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
Study NCT02174172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
Study NCT02174172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Description: Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
Study NCT02174172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
Study NCT02174172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
Study NCT02174172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2a
Description: Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
Study NCT03414632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 99mTc-PYP
Description: Radioisotope used in the SPECT/CT imaging
Study NCT03291015 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: radiographic
Description: using plain x ray to determind the treatment plan
Study NCT03291015 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: arthroscopy
Description: using wrist arthroscopy to determind the treatment plan
Study NCT00580398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
Study NCT00580398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
Study NCT04697706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moonstone
Description: Participants will take one packet of Moonstone powder reconstituted in 500 ml water, twice a day, to total 1 L per day (66 meq of potential alkali/day) plus ad lib fluids. Moonstone packets will be supplied by Dr. Arnie's, Inc.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period.
Study NCT04697706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Participants will take in 1L of tap water per day plus ad lib, self-selected fluids.~Participants will follow their own self-chosen ad lib diets and complete a diet diary (Appendix) for days 6 and 7 in the first study period. On day 7, a 24-hour urine collection will be performed, and a 50-ml aliquot of urine will be sent to Litholink (Chicago, IL) via FedEx for analysis. Participants will then continue to the second study period and will use the diet diary completed in the first study period on days 6 and 7 to reproduce the identical diets for days 6 and 7 of the subsequent collection period.
Study NCT00932854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS
Description: Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
Study NCT01771913 — intervention group
Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: centrifuged fat graft
Description: fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
Study NCT01771913 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: ADSCs enriched fat graft
Description: fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
Study NCT03852576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP/QRH dimer
Description: KSP-QRH-E3-IRDye800 (Peptide 919288G)
Study NCT01407419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Acceleration
Description: Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)
Study NCT01407419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Assessment
Description: Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
Study NCT03847077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPad counseling
Description: Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.
Study NCT03847077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Counseling
Description: Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
Study NCT01597232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion trigger based on WCPTS
Description: Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
Study NCT01597232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of hemoglobin level more than 10g/dL
Description: The patient's hemoglobin level is maintained more than 10g/dL perioperatively
Study NCT01597232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion trigger based on experience
Description: Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience